Crohn’s disease; Magnetic Resonance Imaging; Remission; Response; Transmural Healing
Abstract :
[en] BACKGROUND & AIMS: Cross-sectional imaging is an integral part of evaluating disease activity and complications in Crohn's disease. There remains a need to develop guidance that may be for both clinical trials and clinical practice. This initiative aimed to develop consensus statements for definitions of response and remission, transmural healing, optimal timing for assessing, and evaluation of treatment efficacy in patients with Crohn's disease using magnetic resonance enterography in clinical trials and clinical practice. METHODS: Thirty-three international experts (gastroenterologists [n = 29] and radiologists [n = 4] participated in a consensus process. A systematic literature review was conducted to inform initial consensus, and statements were discussed and voted on using a modified Delphi method. Consensus was defined as at least 75% agreement among voters. RESULTS: The Magnetic Resonance Index of Activity (MaRIA) score and the simplified MaRIA score should be used to determine response and remission in moderate-to-severe Crohn's disease. Response was defined as a MaRIA score <11 or an improvement of at least 25%, and a decrease of at least 1 point in the simplified MaRIA score. Remission was defined as a MaRIA score <7 or a simplified MaRIA score <1. Five different definitions were proposed for transmural healing. For the time point of assessment, the group proposed week 24 for response; weeks 24, 52, or 54 for remission; and weeks 52 or 104 for transmural healing. CONCLUSIONS: A consensus expert panel has developed standardized definitions of magnetic resonance enterography response, remission, and the optimal timing for response assessment in patients with luminal Crohn's disease. Further research is needed to clarify the method for measuring transmural healing.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Caron, Bénédicte; INFINY Institute, Inserm, NGERE, Nancy University Hospital, University of Lorraine, Nancy, France.
Jairath, Vipul; Translational Gastroenterology Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, United Kingdom, Lawson Health Research Institute, London Health Science Centre, London, Ontario, Canada, Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
Sands, Bruce E; Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Rubin, David T; Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, Illinois.
Allocca, Mariangela; Gastroenterology and Endoscopy, IRCCS Hospital San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
Laurent, Valérie; Laboratoire IADI, INSERM U1254, Department of Radiology, University Hospital of Nancy, Nancy, France.
Novak, Kerri; Division of Gastroenterology & Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Alberta, Canada.
Panaccione, Remo; Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada.
Bossuyt, Peter; Imelda GI Clinical Research Center, Imelda General Hospital, Bonheiden, Belgium.
Bruining, David H; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Dignass, Axel; Department of Medicine I, Agaplesion Markus Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
Dotan, Iris; Division of Gastroenterology, Rabin Medical Center, Petah-Tikva, Israel, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Fletcher, Joel; Department of Radiology, Mayo Clinic, Rochester, Minnesota.
Fumery, Mathurin; Department of Gastroenterology, CHU Amiens, Amiens, France, PériTox, UMR-I 01 INERIS, Picardie Jules Verne University, Amiens, France.
Furfaro, Federica; Gastroenterology and Endoscopy, IRCCS Hospital San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
Halfvarson, Jonas; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Hart, Ailsa; IBD Unit, St Mark's Hospital and Imperial College London, London, United Kingdom.
Kobayashi, Taku; Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
Cleveland, Noa Krugliak; Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, Illinois.
Kucharzik, Torsten; Department of Gastroenterology, Klinikum Lüneburg, Lüneburg, Germany, Westfälische Wilhelms Universität Münster, Münster, Germany.
Laghi, Andrea; Department of Medical Surgical Sciences and Translational Medicine, AOU Sant'Andrea, Sapienza University of Rome, Rome, Italy.
Lakatos, Peter L; Division of Gastroenterology and Hepatology, McGill University Health Center, Montreal, Quebec, Canada, Department of Oncology and Medicine, Semmelweis University, Budapest, Hungary.
Leong, Rupert W; Department of Gastroenterology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
Loftus, Edward V Jr; Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Magro, Fernando; Centre for Health Technology and Services Research, Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.
Olivera, Pablo A; Zane Cohen Centre for Digestive Diseases, Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, Gastroenterology Section, Department of Internal Medicine, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Buenos Aires, Argentina.
Shaji, Sebastien; IBD Unit, Department of Gastroenterology, Hull University Teaching Hospitals, Hull, United Kingdom.
Siegmund, Britta; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Vavricka, Stephan R; Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Danese, Silvio; Gastroenterology and Endoscopy, IRCCS Hospital San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
Stoker, Jaap; Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, the Netherlands, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, the Netherlands.
Peyrin-Biroulet, Laurent; INFINY Institute, Inserm, NGERE, Nancy University Hospital, University of Lorraine, Nancy, France. Electronic address: peyrinbiroulet@gmail.com.
International Magnetic Resonance Imaging Consensus for use in Luminal Crohn's Disease Trials and Clinical Practice.
Publication date :
27 August 2025
Journal title :
Clinical Gastroenterology and Hepatology
ISSN :
1542-3565
eISSN :
1542-7714
Publisher :
Saunders, Philadelphia, Us pa
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
The consensus was supported by Materia Prima via Roche, Sanofi, and
Takeda. The funders had no role in study design; the collection, analysis, and
interpretation of data; the writing of the report; and the decision to submit the
paper for publication.
Ordas I, Rimola J, Rodriguez S, et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn’s disease. Gastroenterology. 2014;146:374-382.e1.
Pouillon L, Laurent V, Pouillon M, et al. Diffusion-weighted MRI in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2018;3:433-443.
Hanzel J, Jairath V, Ma C, et al. Responsiveness of magnetic resonance enterography indices for evaluation of luminal disease activity in Crohn’s disease. Clin Gastroenterol Hepatol. 2022;20:2598-2606.
Rimola J, Torres J, Kumar S, Taylor SA, Kucharzik T. Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease. Gut. 2022;71:2587-2597.
Hordonneau C, Buisson A, Scanzi J, et al. Diffusion-weighted magnetic resonance imaging in ileocolonic Crohn’s disease: validation of quantitative index of activity. Am J Gastroenterol. 2014;109:89-98.
Rimola J, Rodriguez S, Garcia-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease. Gut. 2009;58:1113-1120.
Ordas I, Rimola J, Alfaro I, et al. Development and validation of a simplified magnetic resonance index of activity for Crohn’s disease. Gastroenterology. 2019;157:432-439.e1.
Steward MJ, Punwani S, Proctor I, et al. Non-perforating small bowel Crohn’s disease assessed by MRI enterography: derivation and histopathological validation of an MR-based activity index. Eur J Radiol. 2012;81:2080-2088.
Oussalah A, Laurent V, Bruot O, et al. Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut. 2010;59:1056-1065.
European Medicines Agency. Guideline on the development of new medicinal products for the treatment of Crohn’s Disease. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-new-medicinal-products-treatment-crohns-disease-revision-2_en.pdf. Accessed •••.
Caron B, Jairath V, Laurent V, et al. Defining magnetic resonance imaging treatment response and remission in Crohn’s disease: a systematic review. J Crohns Colitis. 2024;18:162-170.
Geyl S, Guillo L, Laurent V, et al. Transmural healing as a therapeutic goal in Crohn’s disease: a systematic review. Lancet Gastroenterol Hepatol. 2021;6:659-667.
Coimbra AJF, Rimola J, O’Byrne S, et al. Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn’s disease, and may help select subjects with active inflammation. Aliment Pharmacol Ther. 2016;43:61-72.
Gottlieb K, Daperno M, Usiskin K, et al. Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments. Gut. 2021;70:418-426.
D’Amico F, Chateau T, Laurent V, et al. Which MRI score and technique should be used for assessing Crohn’s disease activity? J Clin Med. 2020;9:1691.
Lee WE, Weng MT, Wei SC, et al. Comparison of the magnetic resonance scoring systems for Crohn’s disease activity: MaRIA, simplified MaRIA, and Nancy scores. Abdom Radiol N Y. 2023;48:2228-2236.
Williet N, Jardin S, Roblin X. The Simplified Magnetic Resonance Index of Activity (MARIA) for Crohn’s disease is strongly correlated with the MARIA and Clermont score: an external validation. Gastroenterology. 2020;158:282-283.
Fernandez-Clotet A, Sapena V, Capozzi N, et al. Avoiding contrast-enhanced sequences does not compromise the precision of the simplified MaRIA for the assessment of non-penetrating Crohn’s disease activity. Eur Radiol. 2022;32:3334-3345.
Buisson A, Junda J, Vignette J, et al. Development and validation of a score to assess transmural healing and response in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2024;22:2271-2279.e11.
Fernandes SR, Rodrigues RV, Bernardo S, et al. Transmural healing is associated with improved long-term outcomes of patients with Crohn’s disease. Inflamm Bowel Dis. 2017;23:1403-1409.
Buisson A, Hordonneau C, Goutorbe F, et al. Bowel wall healing assessed using magnetic resonance imaging predicts sustained clinical remission and decreased risk of surgery in Crohn’s disease. J Gastroenterol. 2019;54:312-320.
Lafeuille P, Hordonneau C, Vignette J, et al. Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn’s disease. Aliment Pharmacol Ther. 2021;53:577-586.
Takenaka K, Kawamoto A, Kitazume Y, et al. Transmural remission characterized by high biologic concentrations demonstrates better prognosis in Crohn’s disease. J Crohns Colitis. 2023;17:855-862.
Fernandes SR, Serrazina J, Botto IA, et al. Transmural remission improves clinical outcomes up to 5 years in Crohn’s disease. United Eur Gastroenterol J. 2023;11:51-59.
Messadeg L, Hordonneau C, Bouguen G, et al. Early transmural response assessed using magnetic resonance imaging could predict sustained clinical remission and prevent bowel damage in patients with Crohn’s disease treated with anti-tumour necrosis factor therapy. J Crohns Colitis. 2020;14:1524-1534.
Kumar S, De Kock I, Blad W, et al. Magnetic resonance enterography and intestinal ultrasound for the assessment and monitoring of Crohn’s disease. J Crohns Colitis. 2024;18:1450-1463.
Schaefer M, Laurent V, Grandmougin A, et al. A magnetic resonance imaging index to predict Crohn’s disease postoperative recurrence: the MONITOR index. Clin Gastroenterol Hepatol. 2022;20:e1040-e1049.
